# Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)

> **NCT04888663** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 50 (actual)

## Conditions studied

- Recurrent/Metastatic Gastric Cancer

## Interventions

- **DRUG:** Trastuzumab + Ramucirumab + Paclitaxel

## Key facts

- **NCT ID:** NCT04888663
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-02-13
- **Primary completion:** 2021-09-02
- **Final completion:** 2021-09-02
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2021-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04888663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04888663, "Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04888663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*